

# Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab)

Recombinant Antibody

Catalog # APR10092

## Product Information

---

|                          |                            |
|--------------------------|----------------------------|
| <b>Application</b>       | FC, Kinetics, Animal Model |
| <b>Primary Accession</b> | <a href="#">P20138</a>     |
| <b>Reactivity</b>        | Human                      |
| <b>Clonality</b>         | Monoclonal                 |
| <b>Isotype</b>           | IgG4SP                     |
| <b>Calculated MW</b>     | 39825                      |

## Additional Information

---

|                           |  |
|---------------------------|--|
| <b>Target/Specificity</b> | Siglec-3 / CD33  |
| <b>Endotoxin</b>          |  |
| <b>Conjugation</b>        | Unconjugated   |
| <b>Expression system</b>  | CHO Cell   |
| <b>Format</b>             | Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column. |


## Protein Information

---


|                 |  |
|-----------------|--|
| <b>Name</b>     | CD33   |
| <b>Synonyms</b> | SIGLEC3  |
| <b>Function</b> | <p>Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state (PubMed:<a href="#">10611343</a>, PubMed:<a href="#">11320212</a>, PubMed:<a href="#">15597323</a>). Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans (PubMed:<a href="#">7718872</a>). Upon engagement of ligands such as C1q or sialylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK (PubMed:<a href="#">10887109</a>, PubMed:<a href="#">28325905</a>). These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:<a href="#">10206955</a>, PubMed:<a href="#">10556798</a>, PubMed:<a href="#">10887109</a>). In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules (PubMed:<a href="#">10206955</a>, PubMed:<a href="#">10887109</a>). One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K (PubMed:<a href="#">15597323</a>).</p> |

|                          |   |
|--------------------------|---|
| <b>Cellular Location</b> | [Isoform CD33M]: Cell membrane; Single-pass type I membrane protein                         |
| <b>Tissue Location</b>   | Monocytic/myeloid lineage cells. In the brain, CD33 is mainly expressed on microglial cells |


## Images



Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab) is more than 99.54% ,determined by SEC-HPLC.



Immobilized human CD33 His at 2 µg/mL can bind Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab),EC50=0.00433 µg/mL

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.